JY
BCAX

Jeff Yass’s Bicara Therapeutics BCAX Stock Holding History

Jeff Yass’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$843K Sell
28,400
-37,000
-57% -$826K ﹤0.01% 8630
2026
Q1 		$1.3M Buy
65,400
+4,600
+8% +$79.2K ﹤0.01% 7230
2025
Q4 		$1.02M Buy
60,800
+47,800
+368% +$816K ﹤0.01% 7140
2025
Q3 		$205K Buy
+13,000
New +$146K ﹤0.01% 10938

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's BCAX Position: Q2 2026 in Review

Jeff Yass sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 10,944 shares — an estimated $244K sold.

Jeff Yass first reported a position in BCAX in Q1 2025 and held it in 4 quarters. The position peaked at $517K in Q4 2025. 169 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Jeff Yass reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 10,944 Bicara Therapeutics shares in Q2 2026, an estimated $244K.
  • Jeff Yass first reported a position in Bicara Therapeutics in Q1 2025 and held it in 4 quarters.
  • Jeff Yass's Bicara Therapeutics position peaked at $517K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.